KDR and cancer: FTB (GSK1363089, Fig. 1) is a multikinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor-2 (VEGFR) and mesenchymal–epithelial transition factor (MET), with the capability for solid tumors treatment.6 GlaxoSmithKline launched many clinical trials for FTB in many types of cancers but in 2015, it suddenly discontinued their clinical studies for FTB.